AQR Capital Management LLC Has $2.50 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

AQR Capital Management LLC grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,773 shares of the biopharmaceutical company’s stock after acquiring an additional 2,265 shares during the quarter. AQR Capital Management LLC’s holdings in Halozyme Therapeutics were worth $2,501,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Rise Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the first quarter valued at $25,000. Whittier Trust Co. bought a new stake in Halozyme Therapeutics in the 1st quarter valued at $27,000. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 254 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $33,000. Finally, Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $49,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HALO. Benchmark reissued a “buy” rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. TD Cowen raised their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $58.00 to $62.00 in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of Halozyme Therapeutics in a report on Friday, October 4th. Finally, Morgan Stanley upped their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.44.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $54.13 on Wednesday. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21. The firm has a 50 day simple moving average of $58.90 and a 200 day simple moving average of $50.61. Halozyme Therapeutics, Inc. has a fifty-two week low of $32.83 and a fifty-two week high of $65.53. The firm has a market cap of $6.89 billion, a P/E ratio of 22.37, a P/E/G ratio of 0.56 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.68 earnings per share. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at $40,063,244.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the transaction, the chief financial officer now directly owns 15,480 shares in the company, valued at approximately $834,836.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the transaction, the chief executive officer now owns 676,744 shares in the company, valued at $40,063,244.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 84,881 shares of company stock worth $4,932,284 over the last ninety days. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.